News

NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals

NEW YORK , May 11, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, May 7, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: Bank of America 2021 Healthcare Conference on Wednesday, May 12 at 9:30 a.m. EDT 7^th Annual Truist Securities Life Sciences

NEW YORK, NY, April 21, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, April 21, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, to expand MSCI’s thematic index suite with the launch of new indexes

NEW YORK, NY, April 15, 2021 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share. The dividend will be paid on June 15, 2021, to shareholders of record at the close of business on May 20, 2021.

NEW YORK, NY and LEXINGTON, MA, April 8, 2021 – Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of

NEW YORK, NY, April 1, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million and up to $50 million in additional payments contingent on

NEW YORK, NY, March 30, 2021 – The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc.

NEW YORK , Feb. 17, 2021 - Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow $2.4 billion of acquisitions announced in 2020; maintained leading share of biopharma royalty funding market Increasing outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%